There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH ... and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare ...

12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

The incretin effect is impaired in patients with Type 2 diabetes. Exogenous administration of GLP-1 stimulates insulin secretion, inhibits glucagon secretion, slows gastric emptying, decreases ...

announced on Wednesday that it has received approval from the independent ethics board for its GLP-1-H25-5 human pilot study. The study will test an oral version of liraglutide, formulated using ...

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has completed its submission to the human research ethics ...

Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to begin to implement and execute human pilot study GLP-1 ...